Abstract
The majority of patients with advanced prostate cancer (PC) develop bone metastases that can result in skeletal-related events (SREs) including pathologic fracture, spinal cord compression, hypercalcemia of malignancy, and radiotherapy or surgery to bone. Zoledronic acid has demonstrated efficacy in reducing and delaying SREs in patients with hormone-refractory prostate cancer (HRPC). Bone metastases in patients with recurrent PC are now often diagnosed earlier in the course of disease progression, often before the onset of SREs or bone pain.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
